Micardis Expanded Prophylactic Indication Faces Safety Hurdle
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s cardio-renal advisory committee meets July 29 to assess comparative data to ramipril (the now generic Altace).
You may also be interested in...
King’s Cardiac Imaging Drug Binodenoson Gets Committee Review
CorVue would compete with Astellas’ Lexiscan in a market that has seen many product development failures recently.
BI/Abbott Will Promote Micardis and Mobic With 1,200 Sales Reps
Abbott/Boehringer Ingelheim's combined promotional force for Micardis will total 1,200 sales reps when joint promotional efforts begin in April.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.